increment posit hematolog deal
hope begin
view deal increment deal compani still need
larger deal supplement risk associ
revlimid loss exclus long term increas
target price ad sale
fedratinib account deal dynam celgen acquir impact
biomedicin up-front anoth upon approv lead
asset fedratinib could payment base sale mileston
addit indic dont model base case
think sort deal could address revenu lost relev
recent fail lymphoma studi howev still want see late
stage commerci deal next month sinc celgen alreadi
strong sale forc hematolog think increas commerci
expens deal neglig model around
addit top-line sale fedratinib ep
increas ep
risk outperform target price includ clinic
regulatori setback key product ozanimod
luspatercept ep slightli lower vs
previous model slightli increas near term associ
fedratinib
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
celgen biotechnolog compani focus research
develop commerci therapeut cancer
inflamm immunolog
price jan rate outperform target price analyst alethia young
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky scenario assum greater success pipelin
specif base case assign credit
luspatercept ozanimod
grey sky scenario assum less success pipelin
specif base case remov credit key pipelin
program luspatercept ozanimod
new market model fedratinib suggest may sell roughli peak
credit given second-lin myelofibrosi sale peak sale
would suggest roughli multipl base up-front regulatori mileston
excess view howev sale becom signific celgen
pay sale mileston would factor
multipl calcul think jakafi resist intoler patient key market
opportun fedratinib model jakafi popul
assum sale fedratinib second line peak penetr
modest sale first line peak share given compani
guidanc file fedratinib would estim drug approv late
second-lin data fedratinib look encourag still high unmet
need popul phase singl arm trial link fedratinib
show respons end cycl patient resist
intoler jakafi analysi ruxolitinib studi show outcom patient
discontinu ruxolitinib poor
transplant proport ruxolitinib patient discontinu treatment
estim year year year due
advers event diseas progress death model opportun
indic beyond myelofibrosi
believ outperform tp remain market leader first-
line mf pv high unmet need second line patient
resist jakafi dont think direct threat due jakafi
domin posit mf think hard fedratinib gain signific share
nave popul consid similar target efficaci profil phase
trial efficaci safeti profil fedratinib unlik put ahead
jakafi treatment especi consid potenti neuro toxic fedratinib
previous develop sanofi put clinic hold fda due case
wernick encephalopathi specif patient phase trial
develop addit patient develop fedratinib
studi typic due thiamin defici case report phase
high dose vs lower mg dose group remain unsur whether
tox profil better lower dose cohort compar ruxolitinib
high rate anemia thrombocytopenia fedratinib exhibit higher rate gi
toxic like diarrhea vomit
question curiou learn compani yet
spoken manag deal question view market size
posit product nave refractori refractori studi
support approv pivot thought safeti profil compar market
leader ruxolitinib detail might gain share
develop plan
compani mention price
